logo

Unum Therapeutics Inc. (UMRX)



Trade UMRX now with
  Date
  Headline
12/2/2018 9:02:37 PM Unum Therapeutics Presents Preliminary Results From Ongoing Phase 1 Study ATTCK-20-03
12/1/2018 10:52:50 PM Unum Therapeutics Presents Preliminary Results From Ongoing Phase 1 Study ATTCK-17-01 At The 2018 ASH Annual Meeting
11/13/2018 7:27:07 AM Wedbush Is Cutting Unum Therapeutics Inc. (UMRX) FY18 Rev. Estimate To 9.5 M From 9.6 M
11/13/2018 7:26:55 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q4 18 Rev. Estimate To 3.6 M From 2.9 M
11/13/2018 7:26:30 AM Wedbush Is Lowering Unum Therapeutics Inc. (UMRX) FY19 Estimate To -1.48 From -1.45
11/13/2018 7:26:16 AM Wedbush Is Increasing Unum Therapeutics Inc. (UMRX) Q4 19 Estimate To -0.36 From -0.41
11/13/2018 7:26:04 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q3 19 Estimate To -0.35 From -0.38
11/13/2018 7:25:50 AM Wedbush Is Lowering Unum Therapeutics Inc. (UMRX) Q2 19 Estimate To -0.39 From -0.35
11/13/2018 7:25:38 AM Wedbush Is Cutting Unum Therapeutics Inc. (UMRX) Q1 19 Estimate To -0.37 From -0.31
11/13/2018 7:25:24 AM Wedbush Is Increasing Unum Therapeutics Inc. (UMRX) FY18 Estimate To -1.67 From -1.72
11/13/2018 7:25:10 AM Wedbush Is Increasing Unum Therapeutics Inc. (UMRX) Q4 18 Estimate To -0.36 From -0.39
11/12/2018 4:02:45 PM Unum Therapeutics Q3 Loss/share $0.34 Vs. Loss $0.69 Year Ago
9/18/2018 6:49:15 AM Wedbush Reiterates Unum Therapeutics Inc. (UMRX) At Outperform With $20 Price Target
9/17/2018 7:08:13 AM Unum Therapeutics To Present Data On Dose Level 1 Of The ATTCK-20-03 Phase I Study Of ACTR707 With Rituximab
8/14/2018 6:41:49 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q4 18 Rev. Estimate To 2.9 M From 2.4 M
8/14/2018 6:41:40 AM Wedbush Is Increasing Unum Therapeutics Inc. (UMRX) Q3 18 Rev. Estimate To 2.9 M From 2.4 M
8/14/2018 6:41:08 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) FY18 Estimate To -1.72 From -1.80
8/14/2018 6:40:51 AM Wedbush Is Raising Unum Therapeutics Inc. (UMRX) Q4 18 Estimate To -0.39 From -0.41